Table 3.
Risk factors for ipsi-LLNM in patients with PTC
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| OR | 95% CI | P value | OR | 95% CI | P value | |
| Sex | 0.690 | 0.418–1.139 | .147 | |||
| Age | 0.726 | 0.454–1.160 | .180 | |||
| Tg (ng/mL) | 2.832 | 1.837–4.365 | .000 | 2.668 | 1.590–4.475 | .000 |
| Anti-Tg (IU/mL) | 2.121 | 1.386–3.245 | .001 | 2.001 | 1.202–3.333 | .008 |
| Anti-TPO (IU/mL) | 1.054 | 0.693–1.603 | .805 | |||
| HT | 0.738 | 0.430–1.267 | .271 | |||
| Nodular goiter | 1.018 | 0.649–1.594 | .940 | |||
| Volume (cm3) | 1.093 | 1.029–1.161 | .004 | |||
| Cystic degeneration | 1.816 | 1.190–2.771 | .006 | |||
| Calcification | 1.989 | 1.298–3.048 | .002 | |||
| IC IAP (mg/mL) | 4.418 | 2.787–7.004 | .000 | 3.691 | 2.170–6.278 | .000 |
| IC IVP (mg/mL) | 2.517 | 1.640–3.863 | .000 | 2.122 | 1.271–3.541 | .004 |
| ETE | 6.350 | 4.012–10.050 | .000 | 6.335 | 3.768–10.651 | .000 |
LLNM Lateral lymph node metastasis, PTC Papillary thyroid carcinoma, OR Odds ratio, CI Confidence interval, HT Hashimoto’s thyroiditis, ETE Extrathyroidal extension, IC Iodine concentration, IAP In the arterial phase, IVP In the venous phase